Silexion Therapeutics Corp (SLXN) News
Track canonical SquawkNews coverage tagged to SLXN, Silexion Therapeutics Corp. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SLXN Launches $2.5M Public Offering
SLXN announces $2.5 million public offering at $0.65 per share
EQUITY | Aug 12, 2026, 12:24 AM UTC
L
SLXN Prices $2.5 Million Public Offering
Silexion Therapeutics announces pricing of $2.5 million public offering
EQUITY | Aug 12, 2026, 12:01 AM UTC
H
Silexion Therapeutics Reports Positive Preclinical Findings
Silexion reports positive preclinical findings for SIL204
EQUITY | Aug 04, 2026, 01:15 PM UTC
H
SLXN Initiates Phase 2/3 Trial
SLXN starts phase 2/3 trial for SIL204
EQUITY | Jul 29, 2026, 11:00 AM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
SLXN Initiates Phase 2/3 Trial
Silexion Therapeutics receives approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
EQUITY | Jun 23, 2026, 12:42 PM UTC